Core Viewpoint - Qiming Medical-B (02500) announced a share transfer agreement where Qiming Medical (Hong Kong) Limited will sell shares to Broncus China Holding Corporation for $15 million, representing approximately 1.05% of the total issued shares of Valgen Holding Corporation as of the announcement date [1] Group 1: Investment Details - The transaction involves the sale of shares for a total consideration of $15 million [1] - The investment company Valgen Holding Corporation is registered and incorporated under Cayman Islands law and primarily provides systemic solutions for mitral and tricuspid regurgitation [1] Group 2: Strategic Focus - The company aims to reallocate resources to develop its core products and support long-term business growth by streamlining its investment portfolio [1] - As a minority financial investor in Valgen, the sale represents an appropriate opportunity for the group to monetize its investment [1] - By divesting non-core business investments, the group expects to strengthen its cash flow, improve its working capital position, enhance overall financial flexibility, and facilitate resource reallocation to its core business [1] Group 3: Capital Management - The board believes that prudent capital management, including this sale, is beneficial for ensuring the sustainable development of the group and enhancing shareholder returns [1]

格隆汇12月29日丨启明医疗-B(02500.HK)公告，于2025年12月29日，卖方啓明医疗(香港)有限公司(为公 司的全资附属公司)与买方Broncus China Holding Corporation订立股份转让协议，据此，卖方同意出售而 买方同意购买销售股份(Valgen的157,800股B轮优先股)，代价为1500万美元，占被投资公司Valgen Holding Corporation于本公告日期已发行股份总数(按全面摊薄及已转换基准)约1.05%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 有關出售被投資公司股份之 須予披露交易 出售事項 於 二 零 二 五 年 十 二 月 二 十 九 日（交 易 時 段 後），賣 方 與 買 方 訂 立 股 份 轉 讓 協 議，據 此，賣方同意出售而買方同意購買銷售股份，代價為15,000,000美元，佔被投資公 司 於 本 公 告 日 期 已 發 行 股 份 總 數（按 全 面 攤 薄 及 已 轉 換 基 準）約1.05%。 上市規則的涵義 由 於 出 售 事 項 的 最 高 適 用 百 分 比 率（根 據 上 市 規 則 第14.07條 計 算）超 過5%但低於 25%，故訂立股份轉讓協議及其項下擬進行的出售事項構成本公司的須予披露 交 ...

（文章来源：每日经济新闻） 每经AI快讯，启明医疗-B(02500.HK)盘中涨超7%，截至发稿涨4.05%，报2.57港元，成交额489.42万港 元。 ...

截至目前，Cardiovalve系统已在欧洲顺利完成确证性临床研究全部150例患者入组，并于今年的伦敦心 脏瓣膜介入治疗会议上正式发布TARGET研究的中期结果，数据表现积极，受到海外研究者专家团队的 认可与好评。此次Cardiovalve系统正式步入CE认证阶段，意味着启明医疗在"四瓣一体"的产品战略布 局上更进一步，在已成熟的主瓣、肺瓣产品线基础上，进一步完善了三尖瓣治疗矩阵。 消息面上，启明医疗近期宣布，Cardiovalve经导管三尖瓣置换系统已正式向欧洲公告机构递交CE认证 的全部申请资料，标志着该产品在欧洲市场的准入进程迈出关键一步。 启明医疗-B(02500)盘中涨超7%，截至发稿，涨4.05%，报2.57港元，成交额489.42万港元。 ...

Group 1 - Haixi New Drug (02637) rose nearly 5%, being a commercial-stage pharmaceutical company with integrated R&D, production, and sales capabilities, and a pipeline of innovative drugs under development [1] - Paige Biopharma-B (02565) increased over 4.1%, with cornerstone investors holding a total of 9.5845 million H shares, accounting for approximately 3.43% of the company's total issued H shares [1] - Naxin Micro (02676) surged over 5% to reach a new high of 118.4 HKD, operating under a fabless model focused on chip R&D and design, outsourcing wafer manufacturing and most packaging testing [1] - Huaxin Building Materials (06655) rose 1.46%, with a major shareholder planning to increase its A-share holdings by no less than 200 million RMB and no more than 400 million RMB within six months [1] Group 2 - Dairy stocks saw an uptick, with Modern Farming (01117) rising 6.21% and Youran Dairy (09858) increasing 6.29%, following the Ministry of Commerce's announcement of temporary countervailing measures against EU dairy imports [2] - Gakos-B (01167) rose over 2.7% after announcing a collaboration with AstraZeneca on its self-developed Pan-KRAS inhibitor JAB-23E73 [2] - Junda Co. (02865) increased over 4.1% after announcing a strategic investment in Shangyi Optoelectronics, focusing on perovskite battery technology applications in space energy [2] - Qiming Medical-B (02500) rose nearly 6% after submitting all application materials for CE MDR certification of its Cardiovalve system in Europe [2] Group 3 - Brain Dynamics-B (06681) saw a slight increase of 0.32%, participating in a national major science and technology project focused on the prevention and treatment of cancer and cardiovascular diseases [3] - Hesai Technology (02525) rose over 3.3% after announcing a strategic partnership with Meituan drones for mass production of its second-generation solid-state lidar [4] Group 4 - Hut8 (HUT.US) continued to rise by 4.13%, with a total increase of 37% over three trading days, following an upgrade of its target price to 85 USD by StoneX [5] - Unusual Machines (UMAC.US) surged 9.24%, with a total increase of 45% over three trading days, after receiving a 3.75 million USD order from Performance Drone Works [5] - Hycroft Mining (HYMC.US) opened with a 10.69% increase, having risen 460% since September, due to successful exploration drilling confirming high-grade silver continuity [6] - Sony (SONY.US) rose 2.1% after acquiring a 41% stake in Peanuts Holdings for 630 million CAD, which holds the rights to the Peanuts comic [7] - Novo Nordisk (NVO.US) increased by 7.3% after the FDA approved its first oral GLP-1 weight loss drug, Wegovy, set to launch in January at a starting price of 149 USD per month [7] - ZIM Integrated Shipping Services (ZIM.US) rose 5.78% as the board evaluates multiple acquisition proposals from strategic investors [7]

启明医疗-B(02500)涨超4%，截至发稿，涨4.64%，报2.48港元，成交额115.62万港元。 消息面上，启明医疗发布公告称，于近日，集团已就Cardiovalve经导管三尖瓣置换系统(Cardiovalve系 统)正式向欧洲公告机构递交CE MDR认证的全部申请资料。这标志着该产品在欧洲市场的准入进程迈 出关键一步。 Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相 比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约 95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简 单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。 ...

Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相 比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约 95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简 单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。 智通财经APP获悉，启明医疗-B(02500)涨超4%，截至发稿，涨4.64%，报2.48港元，成交额115.62万港 元。 消息面上，启明医疗发布公告称，于近日，集团已就Cardiovalve经导管三尖瓣置换系统(Cardiovalve系 统)正式向欧洲公告机构递交CE MDR认证的全部申请资料。这标志着该产品在欧洲市场的准入进程迈 出关键一步。 ...

Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相 比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约 95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简 单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。 智通财经APP讯，启明医疗-B(02500)发布公告，于近日，集团已就Cardiovalve经导管三尖瓣置换系统 (Cardiovalve系统)正式向欧洲公告机构递交CE MDR认证的全部申请资料。 ...

格隆汇12月24日丨启明医疗-B(02500.HK)发布公告，近日，集团已就Cardiovalve经导管三尖瓣置换系统 ("Cardiovalve系统")正式向欧洲公告机构递交CEMDR认证的全部申请资料。 Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相 比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约 95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简 单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。 ...